IL1A and autoinflammatory syndrome: The efficacy of IL-1 inhibition with anakinra or canakinumab has been well documented in several studies of autoinflammatory syndromes, including PAPASH, confirming the pro-inflammatory role of dysregulated IL1 signaling [123,124].